Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Angle reported 'positive' results from the first phase of its ovarian cancer clinical verification study.
The pre-study results demonstrated that the optimisation of the molecular solution had been 'successful, paving the way to initiate the 200 subject ovarian cancer clinical verification study of patients who are presenting with a pelvic mass and scheduled for surgery,' the company said.
The pre-study, undertaken by Dr. Richard Moore and colleagues at the University of Rochester Medical Center Wilmot Cancer Institute, was designed to evaluate the use of ANGLE's cancer imagining platforms as a simple blood test to detect the presence of ovarian cancer in women with a pelvic mass, in a clinical setting and with clinical samples.
The pre-study including the evaluation of blood samples from 26 Stage III/IV ovarian cancer patients and 28 healthy volunteers, the company said.
A positive outcome from the clinical verification study would support ANGLE's plans to launch a clinical assay for the detection of ovarian cancer in women with an abnormal pelvic mass.
This study was expected to start in early in the third quarter of the year and was projected to complete in first quarter of 2020.
At 10:29am: (LON:AGL) Angle PLC share price was -2.5p at 67p